Theranostics 2024; 14(1):379-391. doi:10.7150/thno.89495 This issue Cite

Review

Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches

Shiqi Lu1†, Lunbiao Gan1†, Tong Lu2, Keying Zhang2, Jiayu Zhang2, Xinjie Wu1, Donghui Han2, Chao Xu2, Shaojie Liu2, Fa Yang2,✉, Weijun Qin2,✉, Weihong Wen1,✉

1. Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, Shaanxi 710072, China.
2. Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
† These authors contributed equally to this work.

Citation:
Lu S, Gan L, Lu T, Zhang K, Zhang J, Wu X, Han D, Xu C, Liu S, Yang F, Qin W, Wen W. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches. Theranostics 2024; 14(1):379-391. doi:10.7150/thno.89495. https://www.thno.org/v14p0379.htm
Other styles

File import instruction

Abstract

Graphic abstract

Endosialin, also known as tumor endothelial marker 1 (TEM1) or CD248, is a single transmembrane glycoprotein with a C-type lectin-like domain. Endosialin is mainly expressed in the stroma, especially in cancer-associated fibroblasts and pericytes, in most solid tumors. Endosialin is also expressed in tumor cells of most sarcomas. Endosialin can promote tumor progression through different mechanisms, such as promoting tumor cell proliferation, adhesion and migration, stimulating tumor angiogenesis, and inducing an immunosuppressive tumor microenvironment. Thus, it is considered an ideal target for cancer treatment. Several endosialin-targeted antibodies and therapeutic strategies have been developed and have shown preliminary antitumor effects. Here, we reviewed the endosialin expression pattern in different cancer types, discussed the mechanisms by which endosialin promotes tumor progression, and summarized current therapeutic strategies targeting endosialin.

Keywords: endosialin, TEM1, CD248, tumor progression, angiogenesis, tumor microenvironment, targeted therapy


Citation styles

APA
Lu, S., Gan, L., Lu, T., Zhang, K., Zhang, J., Wu, X., Han, D., Xu, C., Liu, S., Yang, F., Qin, W., Wen, W. (2024). Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches. Theranostics, 14(1), 379-391. https://doi.org/10.7150/thno.89495.

ACS
Lu, S.; Gan, L.; Lu, T.; Zhang, K.; Zhang, J.; Wu, X.; Han, D.; Xu, C.; Liu, S.; Yang, F.; Qin, W.; Wen, W. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches. Theranostics 2024, 14 (1), 379-391. DOI: 10.7150/thno.89495.

NLM
Lu S, Gan L, Lu T, Zhang K, Zhang J, Wu X, Han D, Xu C, Liu S, Yang F, Qin W, Wen W. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches. Theranostics 2024; 14(1):379-391. doi:10.7150/thno.89495. https://www.thno.org/v14p0379.htm

CSE
Lu S, Gan L, Lu T, Zhang K, Zhang J, Wu X, Han D, Xu C, Liu S, Yang F, Qin W, Wen W. 2024. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches. Theranostics. 14(1):379-391.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image